Fertility and Ovarian Reserve in Female Childhood Cancer Survivors
NCT ID: NCT06626282
Last Updated: 2024-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
340 participants
OBSERVATIONAL
2024-10-09
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessing Fertility Potential in Female Cancer Survivors
NCT01143844
Impact of Breast Cancer on Human Folliculogenesis
NCT07148141
Fertility Preservation- Oncology Treatment Effects and Psychological Impact
NCT02515916
The Prospective Observational COMPRAYA Cohort Study
NCT04682470
Co-creation of Pain Science Education for Children Living Beyond Cancer
NCT06345391
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In a cohort of female survivors of paediatric cancer aged of at least 18 years old at the time of evaluation, the main objectives of the project PRINCESS are:
1. to evaluate the impact of low-intermediate dose alkylating agents on ovarian function and fertility;
2. to assess the impact of ovarian tissue cryopreservation, used as fertility preservation technique, on further ovarian function and fertility;
3. to identify new screening tools of premature ovarian insufficiency, using targeted and whole genome methylation techniques.
B. Project Design:
The complementarity of the promoters 'and co-applicants skills allows the building of a national translational team which relies on the pre-clinical, clinical and research expertise of paediatric oncologists (Drs Dedeken, De Ville de Goyet and Piette), endocrinologist (Dre Parent) and gynaecologists (Drs Demeestere, Dolmans, Henry and Jadoul). The promoter and co-promotor will directly supervise Dr Bianca David (PhD student) who will contribute to all aspects of the research. The PhD student will be hosted in the LBTD/GIGA-Cancer/Neurosciences and will benefit from its infrastructure, the help of technicians and the expertise of the AS Parent team for epigenetic studies.
Participants eligible to participate to the PRINCESS project (n=170) and controls (n=170) will be invited by a coordinating nurse to take part to PRINCESS fertility evaluation in the medically assisted reproduction centre of one of the three participating institutions. During the first consultation, the PRINCESS project will be explained to the participants, who will sign an informed consent. The expert, with the help of the coordinating nurse, will present the PRINCESS questionnaire including information about their fertility and parenthood situation to the participant, who will then complete it in privacy. A second consultation will take place after minimum 6 weeks without hormonal contraception and ideally between day 2-5 of the menstrual cycle. During this consultation, clinical, biological and ultrasound evaluations will be performed (see below, data collection). A third consultation will be organized to inform he participants of their results. Participants will be offered a compensation for participating to the study.
C. Data collection
1. Data extracted from the Paediatrics Late Effects project at first paediatric cancer and/or relapse(s) and/or progression(s) and/or second cancer(s)
* Type of cancer
* Dates of diagnosis and end of treatment
* Treatment details (type and doses of chemotherapy, type and field of radiotherapy, type of surgery, stem cell transplantation)
* Fertility preservation measures
* Relevant late effects (endocrine, gynaecology, etc.), defined following the Common Terminology Criteria for Adverse Events, version 4.03 (2010-06-14).
* Vital status at last news
2. Data collected during PRINCESS fertility evaluation
* Height, weight, body mass index
* Puberty history, date of menarche and menstrual cycles history
* Pregnancies, childbirth, use of hormonal therapies, including contraception,
* Menopause substitutive hormonal treatment
* Measurement of LH, FSH, oestradiol, progesterone, prolactin, TSH, T4, AMH levels
* Evaluation of the ovarian reserve by ultra-sound (antral follicle count).
Note: one blood EDTA tube will be collected from each patient and stored in a bio-bank in CHU of Liege for later epigenetics analysis.
Data collected by PRINCESS questionnaire Marital status Lifestyle (tobacco/cannabis/alcohol consumption) Level of education Occupation For children and adolescent female cancer survivors who ever tried to become pregnant: use of medical help (and type), pregnancy course (live birth with or without birth defect, miscarriage, medical abortion, stillbirth)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosed with cancer1 between 01/01/2004 and 31/12/2018
* \<17 years old at diagnosis
* treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF
* alive
* ≥ 18 years-old at time of recruitment.
Exclusion Criteria
18 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
La Fondation contre le cancer, Belgique
UNKNOWN
Centre Hospitalier Universitaire de Liege
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bianca David
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital de la Citadelle
Liège, Wallonia, Belgium
Cliniques Universitaires Saint-Luc
Brussels, , Belgium
HUDERF
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anne Lambert
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023/388
Identifier Type: OTHER
Identifier Source: secondary_id
B7072023000101
Identifier Type: OTHER
Identifier Source: secondary_id
OST 2022/2173
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.